DTI fills the gap that has emerged between university level science, and the late-stage human clinical drug development and sales by pharmaceutical companies. DTI obtains licenses for undervalued drug candidates, documents the utility of the compounds, manufactures them under FDA suitable conditions in concert with its corporate partner, and plans to commercialize the products through agreements with pharmaceutical companies. DTI has acquired worldwide exclusive licenses to six multi-component classes of compounds. Licensed compounds appear to have a dramatic effect in stimulating red and white blood cells, neuron survival, immune response and the lifespan of skin fibroblasts. Forty-five patents have been issued or allowed on these technologies throughout the world and 22 additional patent applications are pending.
All lead compounds are small molecules that have been inexpensive to produce.
Animal studies have shown that these compounds are extremely potent and initial studies indicate there is minimal associated toxicity. A bulk supply of Dovetail Technologies' lead compound has been produced under FDA suitable conditions. As the compound is extremely stable, sufficient quantities for pre-clinical evaluation, clinical testing and initial sales are already available. Management is actively pursuing corporate collaborations to assist with future scientific development, marketing, distribution, and sales. DTI is Dr. Floyd Taub's third biotechnology company to participate in the TAP program.